To see the Accelerator in action, register for our webinar series:
The healthcare sector has always been at the cutting-edge of technology innovation, as new advances continue to offer hope for improvements in clinical services and patient outcomes. However, more recently, healthcare organizations (HCOs) around the world have come to realize that there’s just as much to gain from tapping into the power of cloud and app-based services, Internet of Things (IoT) and wearable devices, AI, and other emerging technologies that are revolutionizing consumer lifestyles and wider industries.
This article was originally posted on the Salesforce blog.
COVID-19 has overwhelmed governments and healthcare resources around the world. This crisis underscores the importance of interoperability — the ability for clinical and non-clinical health IT systems to talk to each other, exchange data, and make use of key information. I’ve spent years advocating the importance of interoperability with CIOs across healthcare providers, payers, and government agencies.
Salesforce named a Leader in Healthcare CRM evaluation
As we continue to digest the final rules from CMS and ONC regarding wide-scale interoperability in healthcare, we’re excited to share some recent news from Forrester: Salesforce Health Cloud has been named a leader in The Forrester Wave™: Healthcare CRM Providers, Q12020, with MuleSoft recognized for its interoperability capabilities!
There has arguably never been a more optimistic time for interoperability in healthcare. The possibility of fully unlocking clinical data touches everything — from reducing costs and improving outcomes to powering telehealth and bringing house calls into the digital age to enabling the next generation of cancer care.
But barriers still remain to achieving interoperability that must be overcome. Below we share the vision we co-announced last summer at the White House for achieving true interoperability and driving transformation in healthcare.
Life sciences companies are facing tougher obstacles in bringing new therapies to market than ever before. With an average drug approval process taking up to 15 years and billions of dollars to complete, new technological advancements are being leveraged to help manage the growing clinical, regulatory, and commercial needs necessary to accelerate time to market.
